Markets closed the day in green on favourable domestic factors,
Top ten billionaires in India.
The booming real estate markets in the National Capital Region, Mumbai and Bangalore registered the highest global yields in 2003, according to the latest updates by Chesterton Meghraj, a global real estate consulting group.
Ranbaxy Group company Fortis Healthcare Ltd on Monday said it plans to have 25 hospitals across the country in the next three years and is looking into the possibility of tapping the capital markets for expansion.
India on Wednesday launched a determined bid to diversify its export basket to China by roping in major corporates, including L&T, Ranbaxy, TCS and NIIT, to showcase their technological prowess in the world's most dynamic market.
The tussle over Ranbaxy patriarch Bhai Mohan Singh's will is set to intensify with his second son Manjit Singh staking claim to his parents assets on Tuesday. The assets include shares of about 40 companies.
Recently, Ranbaxy and Wockhardt too were hauled up.
Benchmark indices finished higher on hopes of economic reforms
The Nifty gained 47 points to close at 3,605.\n\n
The Indian Pharmaceutical Alliance has approached regulator for a dialogue to understand the concern raised by it
USL is already contesting a Karnataka High Court order.
The markets opened flat on the back of weak Asian and US cues
The markets opened in green tracking its Asian peers
Escorts on Wednesday sold its Heart Institute to Ranbaxy-controlled Fortis Health Care for Rs 585 crore (Rs 5.85 billion), group chairman Rajan Nanda announced in New Delhi.
Sun Pharma stock has appreciated at 35% a year for 20 years
Shankar Sharma of First Global says that earnings for HPCL, BPCL can quadruple, factoring in oil bonds.
US markets have been very lucrative for the Indian pharma companies and many companies such as Ranbaxy and Dr Reddy's capitalised on this opportunity.
With rains once again lashing Mumbai, the Sensex opened weak and is now down 20 points at 7616. Nifty is down 8 points at 2304.
'The failures of private businessmen have set back the process of market-oriented reform, though that is the only way forward,' argues T N Ninan.
Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of generics
The year 2015 will be a tough year for mergers and acquisition.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances